Abstract: An amorphous alloy soft magnetic powder contains a particle having a composition with a compositional formula (Fe1-xCrx) a (Si1-yBy)100-a-bCb expressed by an atomic ratio, in which 0<x?0.06, 0.3?y?0.7, 70.0?a?81.0, and 0<b?3.0, and when XAFS measurement is performed with an analysis depth set to a bulk, an obtained Fe—K absorption edge XANES spectrum has a first absorption edge structure having a peak A present in a range of 7113±1 eV and a first continuous band structure positioned at a higher energy side than the first absorption edge structure, and an intensity of the peak A at 7113 eV is 0.60 or more and 0.90 or less when an intensity of the first continuous band structure is 1.

Abstract: The present invention provides a method for selecting a cancer patient for whom a combination therapy with a retinoid and a cancer treatment agent is effective, which comprises a step of selecting a cancer patient having a malignant tumor with the infiltration of cancer-associated fibroblasts in the stroma. In addition, the present invention provides a medicament which comprises a cancer patient having a malignant tumor with the infiltration of cancer-associated fibroblasts in the stroma is a subject and is administered in combination of a retinoid and a cancer therapeutic agent.

Abstract: An information management apparatus, comprising a transmitting unit that transmits service information on a given service to a plurality of users, and a calculation unit that for each of the users of the service, calculates a degree of familiarity with a given dealer as to the service, wherein the service information includes sub-information for each of the users to use to proceed with a procedure for receiving the service, the calculation unit calculates the degree of familiarity, based on a communication history of the user, and the transmitting unit transmits the sub-information to a user whose degree of familiarity is lower than a reference value, and inhibits transmission of the sub-information to a user whose degree of familiarity is higher than the reference value.

Abstract: An anti-MEFLIN antibody and a pharmaceutical composition comprising the antibody is described. The pharmaceutical composition may comprise an antibody-drug conjugate (ADC) of the anti-MEFLIN antibody and a cytotoxic agent, which may be connected to each other by a linker. The pharmaceutical composition may be used in the treatment of a cancer in a subject.

Abstract: An object of the present invention is to provide a novel marker that can be used to predict the effect of anti-PD-1 antibody/anti-PD-L1 antibody therapy with high sensitivity, and use thereof. Provided is a biomarker for predicting the effect of anti-PD-1 antibody/anti-PD-L1 antibody therapy, including an immunoglobulin superfamily containing leucine-rich repeat (ISLR).

Abstract: Provided are a knockout mouse, a method for screening a substance for suppressing mesial temporal lobe epilepsy, and a method for selecting a technique for suppressing mesial temporal lobe epilepsy. A knockout mouse 30 or more days of age that has lost the function of the Girdin gene in at least the nervous tissues and exhibits the phenotypes of (1), (2), and (3) below. (1) hippocampal sclerosis should be present, (2) extrahippocampal brain damage should be limited, and (3) spontaneous epilepsy that can be said to be of hippocampal origin should be present.

Abstract: Provided are a knockout mouse, a method for screening a substance for suppressing mesial temporal lobe epilepsy, and a method for selecting a technique for suppressing mesial temporal lobe epilepsy. A knockout mouse 30 or more days of age that has lost the function of the Girdin gene in at least the nervous tissues and exhibits the phenotypes of (1), (2), and (3) below. (1) hippocampal sclerosis should be present, (2) extrahippocampal brain damage should be limited, and (3) spontaneous epilepsy that can be said to be of hippocampal origin should be present.

Abstract: The purpose of the present invention is to provide: a biomarker specific to lymphocytic infundibuloneurohypophysitis; and use applications of the biomarker. Provided are: a biomarker comprising an anti-rabphilin 3a antibody; and a test method using the biomarker.

Abstract: Antibodies are provided that specifically bind to Acting Binding Protein Girdin (Akt Phosphorylation Enhancer), a new substrate of serine/threonine kinase. Additionally, methods of making hybridomas for producing said antibodies and methods of detecting girdin using said antibodies are provided herein. The antibodies and methods are useful for detecting girdin in tissue samples, such as tissue samples from subjects having or suspected of having a disorder in which any of cell motility, cell movement, and angiogenesis is involved.

Abstract: It is intended to identity a protein involved in a molecular mechanism between Akt and cell motility as well as to elucidate its function and find its application. In the present teachings, for achieving the above object, protein or partial peptide thereof containing an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID: 2 is utilized in the screening of a compound or a salt thereof that activates or inhibits any of cell motility, cell migration and angiogenesis.

Abstract: The purpose of the present invention is to provide: a biomarker specific to lymphocytic infundibuloneurohypophysitis; and use applications of the biomarker. Provided are: a biomarker comprising an anti-rabphilin 3a antibody; and a test method using the biomarker.

Abstract: It is intended to identity a protein involved in a molecular mechanism between Akt and cell motility as well as to elucidate its function and find its application. In the present teachings, for achieving the above object, protein or partial peptide thereof containing an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID: 2 is utilized in the screening of a compound or a salt thereof that activates or inhibits any of cell motility, cell migration and angiogenesis.

Abstract: It is intended to identify and provide a novel carnitine transporter gene participating in carnitine transport in the testis and epididymis and carnitine transporter which is a protein encoded by the gene. A protein comprising the amino acid sequence represented by SEQ ID NO: 2 or an amino acid sequence derived therefrom by deletion, substitution or addition of one to several amino acids and being capable of transporting carnitine or its analog; and a gene encoding this protein.

Abstract: It is intended to identify and provide a novel urate transporter gene participating in the urate transport in the kidney and a urate transporter which is a polypeptide encoded by the above gene. Namely, a protein comprising the amino acid sequence represented by SEQ ID NO:1 or an amino acid sequence derived therefrom by deletion, substitution or addition of one to several amino acids and being capable of transporting uric acid and its analogs; and a gene encoding this protein.

Abstract: It is intended to identify and provide a novel carnitine transporter gene participating in carnitine transport in the testis and epididymis and carnitine transporter which is a protein encoded by the gene. A protein comprising the amino acid sequence represented by SEQ ID NO:1 or an amino acid sequence derived therefrom by deletion, substitution or addition of one to several amino acids and being capable of transporting carnitine or its analog; and a gene encoding this protein.

Abstract: A borehole tool positioning and measuring apparatus and its methods of use are provided. The apparatus and method can be used to centralize a logging tool in a wellbore, or position a logging tool at a desired relative alignment relative to the wellbore perimeter surface. The method and apparatuses can be used to determine useful information regarding borehole size and configuration. Various embodiments are useful for centralizing, eccentralizing, and otherwise positioning a borehole tool in a wellbore. Methods of determining borehole size and configuration measurements using a positioning apparatus are also provided.

Abstract: It is intended to identify and provide a novel carnitine transporter gene participating in carnitine transport in the testis and epididymis and carnitine transporter which is a protein encoded by the gene. A protein comprising the amino acid sequence represented by SEQ ID NO:2 or an amino acid sequence derived therefrom by deletion, substitution or addition of one to several amino acids and being capable of transporting carnitine or its analog; and a gene encoding this protein.

Abstract: It is intended to identify and provide a novel urate transporter gene participating in the urate transport in the kidney and a urate transporter which is a polypeptide encoded by the above gene. Namely, a protein comprising the amino acid sequence represented by SEQ ID NO: 1 or an amino acid sequence derived therefrom by deletion, substitution or addition of one to several amino acids and being capable of transporting uric acid and its analogs; and a gene encoding this protein.

Abstract: A borehole tool positioning and measuring apparatus and its methods of use are provided. The apparatus and method can be used to centralize a logging tool in a wellbore, or position a logging tool at a desired relative alignment relative to the wellbore perimeter surface. The method and apparatuses can be used to determine useful information regarding borehole size and configuration. Various embodiments are useful for centralizing, eccentralizing, and otherwise positioning a borehole tool in a wellbore. Methods of determining borehole size and configuration measurements using a positioning apparatus are also provided.

Abstract: It is intended to identify and provide a novel carnitine transporter gene participating in carnitine transport in the testis and epididymis and carnitine transporter which is a protein encoded by the gene. A protein comprising the amino acid sequence represented by SEQ ID NO: 2 or an amino acid sequence derived therefrom by deletion, substitution or addition of one to several amino acids and being capable of transporting carnitine or its analog; and a gene encoding this protein.